Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

U Jansen

Showing results (141-150 of 254) with videos related to

Pageof 26
Sort By:
The Journal of Infectious Diseases|October 13, 2001
Neutralization of human papillomavirus type 11 (HPV-11) by serum from women vaccinated with yeast-derived HPV-11 L1 virus-like particles: correlation with competitive radioimmunoassay titerD R Brown, J T Bryan, J M Schroeder, et al.
Vaccine|January 29, 2013
A phase 2 open-label safety and immunogenicity study of a meningococcal B bivalent rLP2086 vaccine in healthy adultsHelen S Marshall, Peter C Richmond, Michael D Nissen, et al.
Human Vaccines & Immunotherapeutics|October 11, 2018
Coadministration of 13-valent pneumococcal conjugate and quadrivalent inactivated influenza vaccines in adults previously immunized with polysaccharide pneumococcal vaccine 23: a randomized clinical trialAllison R Thompson, Nicola P Klein, H Jackson Downey, et al.
Emerging Microbes & Infections|July 6, 2022
Neutralization of Omicron sublineages and Deltacron SARS-CoV-2 by three doses of BNT162b2 vaccine or BA.1 infectionChaitanya Kurhade, Jing Zou, Hongjie Xia, et al.
The Pediatric Infectious Disease Journal|June 22, 2012
Safety and immunogenicity of a meningococcal B bivalent rLP2086 vaccine in healthy toddlers aged 18-36 months: a phase 1 randomized-controlled clinical trialHelen S Marshall, Peter C Richmond, Michael D Nissen, et al.
The Pediatric Infectious Disease Journal|February 3, 2016
Immunogenicity, Tolerability and Safety in Adolescents of Bivalent rLP2086, a Meningococcal Serogroup B Vaccine, Coadministered with Quadrivalent Human Papilloma Virus VaccineShelly Senders, Prakash Bhuyan, Qin Jiang, et al.
The Journal of Infectious Diseases|April 12, 2024
Respiratory Syncytial Virus Prefusion F Vaccination: Antibody Persistence and RevaccinationEdward E Walsh, Ann R Falsey, Agnieszka M Zareba, et al.
Expert Review of Vaccines|June 9, 2018
From research to licensure and beyond: clinical development of MenB-FHbp, a broadly protective meningococcal B vaccineJohn L Perez, Judith Absalon, Johannes Beeslaar, et al.
The Journal of Infection|August 14, 2016
Safety and immunogenicity of a booster dose of a 3-antigen Staphylococcus aureus vaccine (SA3Ag) in healthy adults: A randomized phase 1 studyHelen Marshall, Michael Nissen, Peter Richmond, et al.
Antimicrobial Agents and Chemotherapy|August 26, 2003
Real-time monitoring of bacterial infection in vivo: development of bioluminescent staphylococcal foreign-body and deep-thigh-wound mouse infection modelsNelly A Kuklin, Gregory D Pancari, Timothy W Tobery, et al.
Pageof 26

Showing results (141-150 of 254) with videos related to

Sort By:
Pageof 26
The Journal of Infectious Diseases|October 13, 2001
Neutralization of human papillomavirus type 11 (HPV-11) by serum from women vaccinated with yeast-derived HPV-11 L1 virus-like particles: correlation with competitive radioimmunoassay titerD R Brown, J T Bryan, J M Schroeder, et al.
Vaccine|January 29, 2013
A phase 2 open-label safety and immunogenicity study of a meningococcal B bivalent rLP2086 vaccine in healthy adultsHelen S Marshall, Peter C Richmond, Michael D Nissen, et al.
Human Vaccines & Immunotherapeutics|October 11, 2018
Coadministration of 13-valent pneumococcal conjugate and quadrivalent inactivated influenza vaccines in adults previously immunized with polysaccharide pneumococcal vaccine 23: a randomized clinical trialAllison R Thompson, Nicola P Klein, H Jackson Downey, et al.
Emerging Microbes & Infections|July 6, 2022
Neutralization of Omicron sublineages and Deltacron SARS-CoV-2 by three doses of BNT162b2 vaccine or BA.1 infectionChaitanya Kurhade, Jing Zou, Hongjie Xia, et al.
The Pediatric Infectious Disease Journal|June 22, 2012
Safety and immunogenicity of a meningococcal B bivalent rLP2086 vaccine in healthy toddlers aged 18-36 months: a phase 1 randomized-controlled clinical trialHelen S Marshall, Peter C Richmond, Michael D Nissen, et al.
The Pediatric Infectious Disease Journal|February 3, 2016
Immunogenicity, Tolerability and Safety in Adolescents of Bivalent rLP2086, a Meningococcal Serogroup B Vaccine, Coadministered with Quadrivalent Human Papilloma Virus VaccineShelly Senders, Prakash Bhuyan, Qin Jiang, et al.
The Journal of Infectious Diseases|April 12, 2024
Respiratory Syncytial Virus Prefusion F Vaccination: Antibody Persistence and RevaccinationEdward E Walsh, Ann R Falsey, Agnieszka M Zareba, et al.
Expert Review of Vaccines|June 9, 2018
From research to licensure and beyond: clinical development of MenB-FHbp, a broadly protective meningococcal B vaccineJohn L Perez, Judith Absalon, Johannes Beeslaar, et al.
The Journal of Infection|August 14, 2016
Safety and immunogenicity of a booster dose of a 3-antigen Staphylococcus aureus vaccine (SA3Ag) in healthy adults: A randomized phase 1 studyHelen Marshall, Michael Nissen, Peter Richmond, et al.
Antimicrobial Agents and Chemotherapy|August 26, 2003
Real-time monitoring of bacterial infection in vivo: development of bioluminescent staphylococcal foreign-body and deep-thigh-wound mouse infection modelsNelly A Kuklin, Gregory D Pancari, Timothy W Tobery, et al.
Pageof 26